Cargando…
Screening for osteoporosis among post-menopausal women in community pharmacy
OBJECTIVES: To identify postmenopausal women with risk of osteoporosis through quantitative ultrasound imaging (QUI) and to value the medical intervention after the determination of the bone mineral density (BMD). METHODS: Cross-sectional descriptive study developed in a community pharmacy. During t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centro de Investigaciones y Publicaciones Farmaceuticas
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166151/ https://www.ncbi.nlm.nih.gov/pubmed/25247006 |
_version_ | 1782335217467392000 |
---|---|
author | Barris Blundell, Damià Rodríguez Zarzuelo, Carmen Sabio Sánchez, Belén Gutiérrez álvarez, José Luis Navarro Visa, Elena Muñoz Valdés, Oscar Garrido Jiménez, Belén Gómez, Rocío Sánchez |
author_facet | Barris Blundell, Damià Rodríguez Zarzuelo, Carmen Sabio Sánchez, Belén Gutiérrez álvarez, José Luis Navarro Visa, Elena Muñoz Valdés, Oscar Garrido Jiménez, Belén Gómez, Rocío Sánchez |
author_sort | Barris Blundell, Damià |
collection | PubMed |
description | OBJECTIVES: To identify postmenopausal women with risk of osteoporosis through quantitative ultrasound imaging (QUI) and to value the medical intervention after the determination of the bone mineral density (BMD). METHODS: Cross-sectional descriptive study developed in a community pharmacy. During the month of June of 2005 the community pharmacy enrolled postmenopausal women into the study. Women in treatment with calcium, vitamin D, hormone replacement therapy, estrogen receptor modulators, calcitonin or biphosphonates were considered criteria for exclusion. To all the women that consent to participate, the pharmacist measured BMD with the device Sahara Hologic Ultrasound Bone Densitometer at right calcaneus. Following the World Health Organization, women were classified as osteoporotic if their T-Score was less than -2.5 and as osteopenic if their T-Score ranged between -2.5 and -1.0. RESULTS: Of the 100 women screened, 11 (11%) presented risk of osteoporosis and 61 (61%) of osteopenia. The 18.5% postmenopausal women with body mass index lesser than 30 presented risk of osteoporosis and the 63.0% osteopenia. CONCLUSIONS: The QUI constitutes a useful tool in community pharmacy for the screening of osteoporosis and it supposes a greater integration of the community pharmacy within the health care. |
format | Online Article Text |
id | pubmed-4166151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Centro de Investigaciones y Publicaciones Farmaceuticas |
record_format | MEDLINE/PubMed |
spelling | pubmed-41661512014-09-22 Screening for osteoporosis among post-menopausal women in community pharmacy Barris Blundell, Damià Rodríguez Zarzuelo, Carmen Sabio Sánchez, Belén Gutiérrez álvarez, José Luis Navarro Visa, Elena Muñoz Valdés, Oscar Garrido Jiménez, Belén Gómez, Rocío Sánchez Pharm Pract (Granada) Original Research OBJECTIVES: To identify postmenopausal women with risk of osteoporosis through quantitative ultrasound imaging (QUI) and to value the medical intervention after the determination of the bone mineral density (BMD). METHODS: Cross-sectional descriptive study developed in a community pharmacy. During the month of June of 2005 the community pharmacy enrolled postmenopausal women into the study. Women in treatment with calcium, vitamin D, hormone replacement therapy, estrogen receptor modulators, calcitonin or biphosphonates were considered criteria for exclusion. To all the women that consent to participate, the pharmacist measured BMD with the device Sahara Hologic Ultrasound Bone Densitometer at right calcaneus. Following the World Health Organization, women were classified as osteoporotic if their T-Score was less than -2.5 and as osteopenic if their T-Score ranged between -2.5 and -1.0. RESULTS: Of the 100 women screened, 11 (11%) presented risk of osteoporosis and 61 (61%) of osteopenia. The 18.5% postmenopausal women with body mass index lesser than 30 presented risk of osteoporosis and the 63.0% osteopenia. CONCLUSIONS: The QUI constitutes a useful tool in community pharmacy for the screening of osteoporosis and it supposes a greater integration of the community pharmacy within the health care. Centro de Investigaciones y Publicaciones Farmaceuticas 2006 2006-07-31 /pmc/articles/PMC4166151/ /pubmed/25247006 Text en Copyright: © Pharmacy Practice http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Barris Blundell, Damià Rodríguez Zarzuelo, Carmen Sabio Sánchez, Belén Gutiérrez álvarez, José Luis Navarro Visa, Elena Muñoz Valdés, Oscar Garrido Jiménez, Belén Gómez, Rocío Sánchez Screening for osteoporosis among post-menopausal women in community pharmacy |
title | Screening for osteoporosis among post-menopausal women in community pharmacy |
title_full | Screening for osteoporosis among post-menopausal women in community pharmacy |
title_fullStr | Screening for osteoporosis among post-menopausal women in community pharmacy |
title_full_unstemmed | Screening for osteoporosis among post-menopausal women in community pharmacy |
title_short | Screening for osteoporosis among post-menopausal women in community pharmacy |
title_sort | screening for osteoporosis among post-menopausal women in community pharmacy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166151/ https://www.ncbi.nlm.nih.gov/pubmed/25247006 |
work_keys_str_mv | AT barrisblundelldamia screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy AT rodriguezzarzuelocarmen screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy AT sabiosanchezbelen screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy AT gutierrezalvarezjoseluis screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy AT navarrovisaelena screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy AT munozvaldesoscar screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy AT garridojimenezbelen screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy AT gomezrociosanchez screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy |